Članki z zahtevami za javni dostop - Milan ScheideggerVeč o tem
Ni na voljo nikjer: 2
Gray matter volume of rostral anterior cingulate cortex predicts rapid antidepressant response to ketamine
A Herrera-Melendez, A Stippl, S Aust, M Scheidegger, E Seifritz, ...
European Neuropsychopharmacology 43, 63-70, 2021
Zahteve: European Commission
Ketamine specifically reduces cognitive symptoms in depressed patients: An investigation of associated neural activation patterns
A Stippl, M Scheidegger, S Aust, A Herrera, M Bajbouj, M Gärtner, ...
Journal of psychiatric research 136, 402-408, 2021
Zahteve: German Research Foundation, European Commission
Na voljo nekje: 22
Increased metabotropic glutamate receptor subtype 5 availability in human brain after one night without sleep
K Hefti, SC Holst, J Sovago, V Bachmann, A Buck, SM Ametamey, ...
Biological psychiatry 73 (2), 161-168, 2013
Zahteve: Swiss National Science Foundation
Sleep deprivation increases dorsal nexus connectivity to the dorsolateral prefrontal cortex in humans
OG Bosch, JS Rihm, M Scheidegger, HP Landolt, P Stämpfli, J Brakowski, ...
Proceedings of the National Academy of Sciences 110 (48), 19597-19602, 2013
Zahteve: Swiss National Science Foundation
Ayahuasca use and reported effects on depression and anxiety symptoms: An international cross-sectional study of 11,912 consumers
J Sarris, D Perkins, L Cribb, V Schubert, E Opaleye, JC Bouso, ...
Journal of Affective Disorders Reports 4, 100098, 2021
Zahteve: National Health and Medical Research Council, Australia
Cerebral mGluR5 availability contributes to elevated sleep need and behavioral adjustment after sleep deprivation
SC Holst, A Sousek, K Hefti, S Saberi-Moghadam, A Buck, SM Ametamey, ...
Elife 6, e28751, 2017
Zahteve: Swiss National Science Foundation
Functional connectivity between prefrontal cortex and subgenual cingulate predicts antidepressant effects of ketamine
M Gärtner, S Aust, M Bajbouj, Y Fan, K Wingenfeld, C Otte, ...
European Neuropsychopharmacology 29 (4), 501-508, 2019
Zahteve: European Commission
In vivo estimation of transverse relaxation time constant (T2) of 17 human brain metabolites at 3T
PO Wyss, C Bianchini, M Scheidegger, IA Giapitzakis, A Hock, A Fuchs, ...
Magnetic resonance in medicine 80 (2), 452-461, 2018
Zahteve: Swiss National Science Foundation, European Commission
Smoking but not cocaine use is associated with lower cerebral metabotropic glutamate receptor 5 density in humans
LM Hulka, V Treyer, M Scheidegger, KH Preller, M Vonmoos, ...
Molecular psychiatry 19 (5), 625-632, 2014
Zahteve: Swiss National Science Foundation
Aberrant working memory processing in major depression: evidence from multivoxel pattern classification
M Gärtner, ME Ghisu, M Scheidegger, L Bönke, Y Fan, A Stippl, ...
Neuropsychopharmacology 43 (9), 1972-1979, 2018
Zahteve: German Research Foundation, European Commission
Glutamatergic and neurometabolic alterations in chronic cocaine users measured with 1H‐magnetic resonance spectroscopy
LM Hulka, M Scheidegger, M Vonmoos, KH Preller, MR Baumgartner, ...
Addiction biology 21 (1), 205-217, 2016
Zahteve: US National Science Foundation, Swiss National Science Foundation
Comparison of four fMRI paradigms probing emotion processing
C Hartling, S Metz, C Pehrs, M Scheidegger, R Gruzman, C Keicher, ...
Brain Sciences 11 (5), 525, 2021
Zahteve: German Research Foundation
Potential therapeutic effects of an ayahuasca-inspired N, N-DMT and harmine formulation: a controlled trial in healthy subjects
HD Aicher, MJ Mueller, DA Dornbierer, D Suay, C Elsner, I Wicki, ...
Frontiers in psychiatry 14, 1302559, 2024
Zahteve: Swiss National Science Foundation
Predicting antidepressant effects of ketamine: the role of the pregenual anterior cingulate cortex as a multimodal neuroimaging biomarker
A Weigand, M Gärtner, M Scheidegger, PO Wyss, A Henning, E Seifritz, ...
International Journal of Neuropsychopharmacology 25 (12), 1003-1013, 2022
Zahteve: European Commission
Overcoming the clinical challenges of traditional ayahuasca: a first-in-human trial exploring novel routes of administration of N, N-Dimethyltryptamine and harmine
DA Dornbierer, L Marten, J Mueller, HD Aicher, MJ Mueller, M Boxler, ...
Frontiers in Pharmacology 14, 1246892, 2023
Zahteve: Swiss National Science Foundation
Not in the drug, not in the brain: Causality in psychedelic experiences from an enactive perspective
D Meling, M Scheidegger
Frontiers in Psychology 14, 1100058, 2023
Zahteve: Swiss National Science Foundation
Comparing mental health across distinct groups of users of psychedelics, MDMA, psychostimulants, and cannabis
A Rougemont-Bücking, H Jungaberle, M Scheidegger, MCG Merlo, ...
Journal of psychoactive drugs 51 (3), 236-246, 2019
Zahteve: Swiss National Science Foundation
A pilot study of cerebral metabolism and serotonin 5-HT2A receptor occupancy in rats treated with the psychedelic tryptamine DMT in conjunction with the MAO …
K Egger, F Gudmundsen, NS Jessen, C Baun, SN Poetzsch, V Shalgunov, ...
Frontiers in Pharmacology 14, 1140656, 2023
Zahteve: Swiss National Science Foundation
Increase in thalamic cerebral blood flow is associated with antidepressant effects of ketamine in major depressive disorder
M Gärtner, M de Rover, L Václavů, M Scheidegger, MJP van Osch, ...
The World Journal of Biological Psychiatry 23 (8), 643-652, 2022
Zahteve: European Commission
Mind the psychedelic hype: Characterizing the risks and benefits of psychedelics for depression
D Meling, R Ehrenkranz, SM Nayak, HD Aicher, X Funk, M van Elk, ...
Psychoactives 3 (2), 215-234, 2024
Zahteve: Swiss National Science Foundation, Netherlands Organisation for Scientific …
Podatke o objavi in financiranju samodejno določi računalniški program